Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Treasury Shares (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Treasury Shares for 4 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • For Q4 2025, Treasury Shares rose 38.1% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $2.5 million, up 38.1%, while the annual FY2025 figure was $2.5 million, 38.1% up from the prior year.
  • Treasury Shares was $2.5 million for Q4 2025 at Day One Biopharmaceuticals, down from $2.8 million in the prior quarter.
  • The five-year high for Treasury Shares was $3.0 million in Q2 2025, with the low at $46625.0 in Q4 2023.
  • Historically, Treasury Shares has averaged $1.4 million across 4 years, with a median of $1.4 million in 2023.
  • The largest annual shift saw Treasury Shares crashed 90.39% in 2023 before it skyrocketed 4634.17% in 2024.
  • Over 4 years, Treasury Shares stood at $485351.0 in 2022, then crashed by 90.39% to $46625.0 in 2023, then soared by 3705.44% to $1.8 million in 2024, then soared by 38.1% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.5 million in Q4 2025, $2.8 million in Q3 2025, and $3.0 million in Q2 2025.